



Technical Bulletin

Lyra and Lyra Direct SARS-CoV-2 Assay CPT and HCPCS Codes

Effective March 13, 2020, the American Medical Association (AMA) has released a new Current Procedural Terminology (CPT®) code for testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), coronavirus disease (COVID-19) using an amplified probe technique.

Effective April 14, 2020, the Centers for Medicare and Medicaid Services (CMS) has released a new CMS Letter Ruling providing higher payment for high throughput SARS-CoV-2 testing and creating new HCPCS codes for the testing of SARS-CoV-2 using an amplified probe technique with the use of high throughput technologies as well as other techniques.

Quidel has identified the following codes as relevant to report the Lyra or Lyra Direct SARS-CoV-2 Assays. Please check with your payers to determine appropriate coding.

Code	Description
87635	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique
U0003	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R.

*For the Medicare Clinical Laboratory Fee Schedule, go to www.cms.gov.

For additional information, please visit the AMA website at:

<https://www.ama-assn.org/practice-management/cpt/cpt-releases-new-coronavirus-covid-19-code-description-testing>

Or the CMS website at:

<https://www.cms.gov/files/document/cms-2020-01-r.pdf>

This information is being provided as a reference, for informational purposes only, with no expressed or implied warranty and does not purport to provide legal or certified coding advice. **Under Federal and State law, it is the individual provider's responsibility to determine appropriate coding, charges and claims for a particular service.** Policies regarding appropriate coding and payment levels can vary greatly from payer to payer and change over

time. Quidel Corporation strongly recommends that providers contact their contracted payers to determine appropriate coding and charge or payment levels prior to submitting claims.

If you have any questions regarding the use of this product, please contact Quidel Technical Support at 1.800.874.1517 (in the U.S.) or technicalsupport@quidel.com. If outside the U.S., further information can be obtained from your distributor, or directly from Quidel at one of the numbers listed below. Reference **quidel.com** to see more options for Support.

Country	Phone	E-Mail Address
Europe, Middle East and Africa	+353 (91) 412 474 (main) 0 1800 200441 (toll free)	emeatechnicalsupport@quidel.com
Austria	+43 316 231239	
France	0 (805) 371674	
Germany	+49 (0) 7154 1593912	
Netherlands	0 800 0224198	
Switzerland	0 800 554864	
United Kingdom	0 800 3688248	
Italy	+39 (800) 620 549	
North America, Asia-Pacific, Latin America	858.552.1100	technicalsupport@quidel.com
Canada	437.266.1704 (main) 888.415.8764 (toll free)	technicalsupport@quidel.com
China	0400 920 9366 or +86 021 3217 8300	chinatechnicalservice@quidel.com

You may also visit our website at **quidel.com** for information on Quidel’s line of Molecular Diagnostics, Rapid Diagnostics, Cell Culture and Specialty Diagnostics (Bone Health and Autoimmune & Complement). Other product information available on our website includes: CPT codes, CLSI procedure guides, SDS, and Package Inserts.

TBM120002EN00 (06/20)